CY1113315T1 - Ιμιδαζολοκαρβοξαμιδια - Google Patents
ΙμιδαζολοκαρβοξαμιδιαInfo
- Publication number
- CY1113315T1 CY1113315T1 CY20121101058T CY121101058T CY1113315T1 CY 1113315 T1 CY1113315 T1 CY 1113315T1 CY 20121101058 T CY20121101058 T CY 20121101058T CY 121101058 T CY121101058 T CY 121101058T CY 1113315 T1 CY1113315 T1 CY 1113315T1
- Authority
- CY
- Cyprus
- Prior art keywords
- preparation
- methods
- imidazolocarboxamides
- imidazolocarboxamide
- anxiety
- Prior art date
Links
- 238000000034 method Methods 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 102100036837 Metabotropic glutamate receptor 2 Human genes 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 108010038421 metabotropic glutamate receptor 2 Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/91—Nitro radicals
- C07D233/92—Nitro radicals attached in position 4 or 5
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Developing Agents For Electrophotography (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8177408P | 2008-07-18 | 2008-07-18 | |
| EP09790351A EP2318375B1 (en) | 2008-07-18 | 2009-07-14 | Imidazole carboxamides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1113315T1 true CY1113315T1 (el) | 2016-04-13 |
Family
ID=41128155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20121101058T CY1113315T1 (el) | 2008-07-18 | 2012-11-07 | Ιμιδαζολοκαρβοξαμιδια |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7754742B2 (enExample) |
| EP (1) | EP2318375B1 (enExample) |
| JP (1) | JP5379227B2 (enExample) |
| KR (1) | KR101287713B1 (enExample) |
| CN (1) | CN102099344B (enExample) |
| AR (1) | AR074631A1 (enExample) |
| BR (1) | BRPI0915977A2 (enExample) |
| CA (1) | CA2731215C (enExample) |
| CY (1) | CY1113315T1 (enExample) |
| DK (1) | DK2318375T3 (enExample) |
| EA (1) | EA018434B1 (enExample) |
| ES (1) | ES2393243T3 (enExample) |
| HR (1) | HRP20120830T1 (enExample) |
| MX (1) | MX2011000611A (enExample) |
| PL (1) | PL2318375T3 (enExample) |
| PT (1) | PT2318375E (enExample) |
| SI (1) | SI2318375T1 (enExample) |
| TW (1) | TW201006801A (enExample) |
| WO (1) | WO2010009062A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI417095B (zh) | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途 |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| KR20100080597A (ko) | 2007-09-14 | 2010-07-09 | 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 | １,３-이치환된-４-페닐-1ｈ-피리딘-2-온 |
| CA2696948C (en) | 2007-09-14 | 2013-04-30 | Jose Maria Cid-Nunez | 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones |
| CA2735764C (en) | 2008-09-02 | 2016-06-14 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
| AU2009304293B2 (en) | 2008-10-16 | 2012-04-26 | Addex Pharma S.A. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| EA020671B1 (ru) | 2009-05-12 | 2014-12-30 | Янссен Фармасьютикалз, Инк. | ПРОИЗВОДНЫЕ 1,2,4-ТРИАЗОЛО[4,3-a]ПИРИДИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2 |
| NZ596078A (en) | 2009-05-12 | 2013-06-28 | Janssen Pharmaceuticals Inc | 1,2,4-TRIAZOLO [4,3-a] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS |
| EP2643320B1 (en) | 2010-11-08 | 2015-03-04 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
| CN103298810B (zh) | 2010-11-08 | 2016-03-16 | 杨森制药公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途 |
| CA2815002C (en) | 2010-11-08 | 2019-10-22 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| EP2681196B1 (en) | 2011-03-04 | 2015-09-09 | Life Technologies Corporation | Compounds and methods for conjugation of biomolecules |
| WO2012131539A1 (en) | 2011-03-31 | 2012-10-04 | Pfizer Inc. | Novel bicyclic pyridinones |
| UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
| WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| LT3431106T (lt) | 2014-01-21 | 2021-02-10 | Janssen Pharmaceutica Nv | Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas |
| KR102414246B1 (ko) | 2014-01-21 | 2022-06-27 | 얀센 파마슈티카 엔.브이. | 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도 |
| TN2017000342A1 (en) | 2015-02-03 | 2019-01-16 | Pfizer | Novel cyclopropabenzofuranyl pyridopyrazinediones |
| CN107207449B (zh) | 2015-04-23 | 2020-11-10 | 豪夫迈·罗氏有限公司 | 用于治疗精神障碍的四唑衍生物 |
| CN104788694B (zh) * | 2015-04-29 | 2018-06-08 | 江苏亚宝绝缘材料股份有限公司 | 一种超低收缩率的聚酰亚胺薄膜 |
| EP3359537B1 (en) | 2015-10-06 | 2020-03-25 | H. Hoffnabb-La Roche Ag | Triazole derivatives |
| JP6905988B2 (ja) | 2016-02-02 | 2021-07-21 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｅａａｔ３阻害剤としてのピラゾール−ピリジン誘導体 |
| CN109071451B (zh) | 2016-05-27 | 2022-07-15 | 豪夫迈·罗氏有限公司 | 作为eaat3抑制剂的吡唑化合物 |
| EP3526201B1 (en) | 2016-10-14 | 2020-11-18 | H. Hoffnabb-La Roche Ag | Imidazole compounds as eaat3 inhibitors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE7897T1 (de) | 1979-09-05 | 1984-06-15 | Glaxo Group Limited | Phenol-derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen. |
| US4666928A (en) | 1984-08-30 | 1987-05-19 | Merck Frosst Canada, Ind. | Propylphenoxy pyridine carboxylates as leukotriene antagonists |
| TW204343B (enExample) | 1991-05-31 | 1993-04-21 | Sumitomo Pharmaceutics Co Ltd | |
| US6800651B2 (en) | 2000-02-03 | 2004-10-05 | Eli Lilly And Company | Potentiators of glutamate receptors |
| JP2006502143A (ja) | 2002-08-26 | 2006-01-19 | メルク エンド カムパニー インコーポレーテッド | 向代謝型グルタミン酸受容体のアセトフェノン増強因子 |
| WO2006014918A2 (en) * | 2004-07-30 | 2006-02-09 | Merck & Co., Inc. | Heterocyclic acetophenone potentiators of metabotropic glutamate receptors |
| AU2005267883A1 (en) | 2004-07-30 | 2006-02-09 | Merck & Co., Inc. | Indanone potentiators of metabotropic glutamate receptors |
| TW200613272A (en) | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
| AU2005299797A1 (en) | 2004-10-25 | 2006-05-04 | Merck & Co., Inc. | Heterocyclic indanone potentiators of metabotropic glutamate receptors |
| ES2333979T3 (es) * | 2004-11-22 | 2010-03-03 | Eli Lilly And Company | Potenciadores de los receptores del glutamato. |
| CN101128435A (zh) | 2004-12-27 | 2008-02-20 | 阿斯利康(瑞典)有限公司 | 作为代谢型谷氨酸受体激动剂用于治疗神经病学及精神病学病症的吡唑酮化合物 |
| CN101309905A (zh) | 2005-08-12 | 2008-11-19 | 阿斯利康(瑞典)有限公司 | 取代的异吲哚酮及其作为代谢型谷氨酸受体增效剂的用途 |
-
2009
- 2009-07-10 TW TW098123468A patent/TW201006801A/zh unknown
- 2009-07-13 AR ARP090102635A patent/AR074631A1/es not_active Application Discontinuation
- 2009-07-14 WO PCT/US2009/050440 patent/WO2010009062A1/en not_active Ceased
- 2009-07-14 JP JP2011518823A patent/JP5379227B2/ja not_active Expired - Fee Related
- 2009-07-14 ES ES09790351T patent/ES2393243T3/es active Active
- 2009-07-14 HR HRP20120830AT patent/HRP20120830T1/hr unknown
- 2009-07-14 PL PL09790351T patent/PL2318375T3/pl unknown
- 2009-07-14 MX MX2011000611A patent/MX2011000611A/es active IP Right Grant
- 2009-07-14 PT PT09790351T patent/PT2318375E/pt unknown
- 2009-07-14 US US12/502,252 patent/US7754742B2/en not_active Expired - Fee Related
- 2009-07-14 SI SI200930350T patent/SI2318375T1/sl unknown
- 2009-07-14 CN CN2009801274345A patent/CN102099344B/zh not_active Expired - Fee Related
- 2009-07-14 EP EP09790351A patent/EP2318375B1/en active Active
- 2009-07-14 KR KR1020117001166A patent/KR101287713B1/ko not_active Expired - Fee Related
- 2009-07-14 DK DK09790351.2T patent/DK2318375T3/da active
- 2009-07-14 EA EA201170227A patent/EA018434B1/ru not_active IP Right Cessation
- 2009-07-14 BR BRPI0915977A patent/BRPI0915977A2/pt not_active IP Right Cessation
- 2009-07-14 CA CA2731215A patent/CA2731215C/en not_active Expired - Fee Related
-
2012
- 2012-11-07 CY CY20121101058T patent/CY1113315T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201170227A1 (ru) | 2011-06-30 |
| SI2318375T1 (sl) | 2012-11-30 |
| PL2318375T3 (pl) | 2013-02-28 |
| TW201006801A (en) | 2010-02-16 |
| US7754742B2 (en) | 2010-07-13 |
| EP2318375A1 (en) | 2011-05-11 |
| CN102099344A (zh) | 2011-06-15 |
| EA018434B1 (ru) | 2013-07-30 |
| PT2318375E (pt) | 2012-10-22 |
| KR101287713B1 (ko) | 2013-07-23 |
| KR20110022676A (ko) | 2011-03-07 |
| CA2731215C (en) | 2013-08-27 |
| US20100016373A1 (en) | 2010-01-21 |
| CA2731215A1 (en) | 2010-01-21 |
| JP5379227B2 (ja) | 2013-12-25 |
| CN102099344B (zh) | 2013-10-30 |
| MX2011000611A (es) | 2011-03-01 |
| BRPI0915977A2 (pt) | 2018-10-30 |
| AR074631A1 (es) | 2011-02-02 |
| JP2011528658A (ja) | 2011-11-24 |
| ES2393243T3 (es) | 2012-12-19 |
| DK2318375T3 (da) | 2012-10-08 |
| HRP20120830T1 (hr) | 2012-11-30 |
| WO2010009062A1 (en) | 2010-01-21 |
| EP2318375B1 (en) | 2012-09-19 |
| AU2009271105A1 (en) | 2010-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123649T1 (el) | Παραγωγα ιμιδαζολινης, μεθοδοι παρασκευης αυτων και εφαρμογες αυτων στην ιατρικη | |
| CY1120297T1 (el) | Ρυθμιστες υποδοχεα ανδρογονου και χρησεις αυτων | |
| CY1122786T1 (el) | Δοσολογικα σχηματα για ενωσεις κατηγοριας εχινοκανδινης | |
| CY1120318T1 (el) | Υποκατεστημενες βενζυλινδαζολες για χρηση ως αναστολεις κινασης bub1 στη θεραπευτικη αντιμετωπιση υπερπολλαπλασιαστικων ασθενειων | |
| CY1120450T1 (el) | Διαμορφωτες υποδοχεων οιστρογονων και χρησεις εξ'αυτων | |
| UY32094A (es) | Derivados heterocíclicos, procesos para su preparación, medicamentos que comprenden dichos compuestos y su uso. | |
| CY1120429T1 (el) | Παραγωγα κιναζολινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων και αλλων νοσων | |
| UY32036A (es) | Derivados de ciclohexil-amida, composiciones farmacéuticas que los contienen, su preparación y aplicaciones | |
| CY1118680T1 (el) | Φαρμακευτικη συνθεση | |
| CL2008000255A1 (es) | Compuestos derivados de 2-aminooxazolinas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de la depresion, ansiedad, trastorno bipolar, esquizofrenia, parkinson, alzheimer | |
| CL2009000860A1 (es) | Compuestos derivados de 4-fenil-4-metil-5,6-dihidro-4h-1,3-tiazina-2-amina; composiciones farmaceuticas que los contienen; y uso de los compuestos en la preparacion de medicamentos inhibidores de bace, utiles para el tratamiento de trastornos mediados por esta enzima, tal como la enfermedad de alzheimer. | |
| EA201170227A1 (ru) | Имидазолкарбоксамиды | |
| CY1112558T1 (el) | Ενωσεις ν-μεθυλαμινομεθυλο ισοϊνδολης και συνθεσεις που τις περιλαμβανουν και μεθοδοι χρησης τους | |
| UY31314A1 (es) | Amidas heterociclicas y sus métodos de uso-976 | |
| CY1113339T1 (el) | Ιμιδαζοκινολινες με ανοσο-ρυθμιστικες ιδιοτητες | |
| CY1112552T1 (el) | Υδροξυμεθυλο πυρρολιδινες ως αγωνιστες β3 αδρενεργικου υποδοχεα | |
| EA201001205A1 (ru) | Соединения, содержащие циклобутоксигруппу | |
| BRPI0910557A2 (pt) | composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e uso. | |
| CR20110100A (es) | Nuevos derivados de sulfamida sustituida | |
| CY1119798T1 (el) | Μορφη iv υδροχλωρικης ιβαμπραδινης | |
| CY1111454T1 (el) | Παραγωγα φαινυλο-πυραζολιου ως συνδετες υποδοχεα μη στεροειδων γλυκοκορτικοειδων | |
| BR112014010708A2 (pt) | pró-fármaco à base de polietilenoglicol de adrenomedulina e utilização do mesmo | |
| CL2008001123A1 (es) | Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer. | |
| NI200900042A (es) | Nuevo derivados de dismetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen. | |
| CY1114960T1 (el) | Συνθεσεις που περιλαμβανουν τραμαδολη και σελεκοξιμπη στην θεραπεια πονου |